Aurinia Pharmaceuticals Inc
AUPH
Company Profile
Business description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Contact
14315 - 118 Avenue
Suite 140
EdmontonABT5L 4S6
CANT: +1 250 708-4272
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,765.70 | 5.40 | -0.06% |
| CAC 40 | 7,683.73 | 58.51 | -0.76% |
| DAX 40 | 23,434.65 | 264.47 | -1.12% |
| Dow JONES (US) | 42,215.80 | 299.29 | -0.70% |
| FTSE 100 | 8,834.03 | 41.19 | -0.46% |
| HKSE | 23,698.65 | 281.65 | -1.17% |
| NASDAQ | 19,521.09 | 180.12 | -0.91% |
| Nikkei 225 | 38,795.11 | 258.37 | 0.67% |
| NZX 50 Index | 12,619.33 | 20.02 | -0.16% |
| S&P 500 | 5,982.72 | 50.39 | -0.84% |
| S&P/ASX 200 | 8,538.60 | 2.70 | -0.03% |
| SSE Composite Index | 3,380.47 | 6.94 | -0.20% |